Safety profile of isocitrate dehydrogenase inhibitors in cancer therapy: a pharmacovigilance study of the FDA Adverse Event Reporting System
The reversible nature of the toxicities associated with IDH inhibitors underscores their promise as a therapeutic agent with a favorable safety profile.
Authors
- Zhaoze Guo (ORCID: https://orcid.org/0000-0001-8847-7740)
- Ruxue Lv (ORCID: https://orcid.org/0009-0002-0181-5052)
- Wenjie Li (ORCID: https://orcid.org/0000-0001-5285-8939)
- Yiming Fu (ORCID: https://orcid.org/0000-0002-1895-4801)
- Ruizhen Li (ORCID: https://orcid.org/0000-0003-0092-4580)
Institutions
- Nanfang Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1080/14740338.2024.2448210
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00